Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
(Nasdaq: INBS) Just Made It To The Top Of The Street Ideas Watchlist For Tomorrow Morning
—Tuesday, September 1, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get Laser Focused On (INBS) Before Tomorrow Morning… August 31, 2026 Dear Reader, With today’s profile reaching $1.58 — approximately 42% above Friday’s $1.11 close — the next chapter shifts to Tuesday. At Street Ideas, the names worth following tend to share a few traits: measurable progress, a product built around a clear need, and developments that continue to add substance to the story. Intelligent Bio Solutions Inc. (Nasdaq: INBS) fits that description. This is a medtech company that has built a proprietary, non-invasive dr-ug screening system — one that collects fingerprint sweat samples in seconds and delivers results in under ten minutes, entirely at the point of collection. The technology screens for opi-ates, co-cai-ne, me-tham-pheta-mine, and can-nab-is without the logistical burden of urine cups, oral swabs, or laboratory infrastructure. The company just reported 38% full-year revenue growth. Gross margin expanded nearly 800 basis points to 48.63%. And all clinical data collection for its FDA 510(k) submission is now complete, with the filing targeting the second half of calendar 2026. That combination — commercial traction that's already compounding, a cost structure that's actively improving, and a regulatory submission approaching the world's largest dr-ug screening market — is what gets our attention at Street Ideas. We look at hundreds of names. Most don't make it past the first screen. The ones that do tend to share a few characteristics: a product that solves a real problem, verified financial momentum, and a clear forward path that the market hasn't fully recognized yet. And the float makes the setup even more compelling… Intelligent Bio Solutions Inc. (Nasdaq: INBS) is topping our watchlist this morning—Tuesday, September 1, 2026.
Yahoo Finance lists the public float for INBS at fewer than 3M shares — a relatively limited supply that makes changes in demand especially worth watching. Recent history provides an example: according to Barchart, INBS went from approximately $1.72 on 8/04/2026 to $3.49 on 8/17/2026, an approximate 102% move in less than two weeks. A Screening Technology Built for the Real World
The dr-ug screening sector has operated on the same basic methods for decades — urine, blood, hair, oral fluid — approaches that require either a clinical setting or significant logistical overhead. The global sector is valued at $8.29B in 2026 and projected to grow to $25.3B by 2036, according to ResearchAndMarkets, reflecting an 11.8% compound annual growth rate driven by workplace safety mandates and the expansion of rapid on-site testing. What Intelligent Bio Solutions Inc. (INBS) has built a system that sidesteps the traditional model entirely. The Intelligent Fingerprinting Dr-ug Screening System analyzes fingerprint sweat through a proprietary process. A donor places a fingertip on a disposable cartridge, the reader device processes the sample, and the result is delivered at the point of collection. 
No specialist knowledge is required to operate it… Think about what that means in practice. A construction site supervisor or a logistics coordinator can administer a screening on-site, in real time, without external specialists, without off-site lab delays, and without the chain-of-custody complexity that traditional methods require. The company's usability study, completed in August 2026, demonstrated exactly that — fifteen operators with no prior experience with the system were trained to administer it effectively. Peter Passaris, Vice President of Product Development, noted that an employer does not want to engage external specialist operators to administer a test — and that this study reinforced the system's field-readiness. That's the kind of practical advantage that resonates across the company's core customer segments: construction, manufacturing, transport and logistics, and mining — all safety-critical environments where operational speed and simplicity directly affect adoption… The company currently serves 502 active customers across the UK, Europe, APAC, and the Middle East. Its reader installed base has grown 22% year-over-year to 1,886 units, and its eighth European patent grant further protects its proprietary technology. Each reader placed in the field generates recurring demand for consumable cartridges — and the fiscal 2026 data shows that cartridge consumption grew 35% year-over-year to 106,500 units, outpacing the rate of hardware placement. That's the razor-razorblade model at work, and the utilization curve is heading in the right direction. Why the FDA Submission Matters Now
The potential catalyst our readers should be focused on is the FDA 510(k) submission… All clinical data collection for the program is now complete. The company is in the final stage of data analysis and package assembly, targeting submission in H2 2026 for codeine detection clearance. If granted, clearance would open the U.S. market — the largest dr-ug screening market on earth — beyond current Forensic Use Only settings, spanning workplace testing, criminal justice, pain management, and substance abuse treatment. The Intelligent Fingerprinting system is already commercially deployed outside the U.S. across workplace, law enforcement, and government environments. What the FDA pathway represents is the chance to bring a proven, field-tested technology into the single largest addressable market in its sector — with the manufacturing cost structure and commercial playbook already in place. The clinical evidence package supporting this submission is substantial, and our readers should understand its scope… Precision testing confirmed reproducibility across more than 1,600 tests, three production runs, and three independent sites — establishing consistency across manufacturing conditions and operating environments. An interference study evaluated the system's performance when exposed to common workplace contaminants including hand creams, oils, dirt, and water — the kind of field-readiness data that addresses whether the technology holds up outside a controlled lab setting. A method comparison study enrolled 135 participants across three U.S. clinical sites, conducted in partnership with CenExel Clinical Research following ICH GCP guidelines. Nine operator participants representing typical workplace screening personnel administered the tests, and all specimens undergo independent LC-MS/MS verification. Independent penetration testing identified no major cybersecurity vulnerabilities, and all review items have been resolved — 100% of medium-risk items remediated and all 19 SBOM vulnerabilities cleared. ISO 13485:2016 recertification aligns the company's quality framework with the FDA's newly amended Quality Management System Regulation — the kind of alignment that signals a company building its regulatory foundation with intention, not just checking boxes. Harry Simeonidis, President and CEO, stated: "We are now firmly in the final stretch of data analysis and assembly of our FDA 510(k) submission package, and we remain focused on bringing our technology to the U.S. market." The Numbers Behind the Momentum
The fiscal 2026 full-year results tell a clear story of a business that is scaling with improving fundamentals… Total revenue reached $4.2M, a 38% increase year-over-year. Gross margin expanded to 48.63%, up 778 basis points — driven by the transition to Syrma Johari as a manufacturing partner expected to deliver 40%+ production cost savings and an estimated 20-percentage-point gross margin improvement. Consumable cartridge output reached 106,500 units, a 35% increase year-over-year, outpacing installed base growth and confirming that existing customers are deepening their utilization of the system. That's the razor-razorblade model generating compounding recurring revenue — and it's working. That last point is worth dwelling on for a moment… When cartridge consumption outpaces hardware placement, it means the customers who already have readers in the field are running more tests per unit. That's a utilization curve heading in the right direction — and it's the kind of leading indicator that suggests the commercial model has real staying power. The company secured a partnership with Bouygues UK, part of global construction group Bouygues Construction, for a dr-ug-testing rollout in a safety-critical construction environment — the type of enterprise-scale deployment that validates the system's commercial readiness. And a rapid screening cartridge targeting 70% faster results is currently in validation, which could further differentiate the system in speed-sensitive field environments… Top 10 Reasons Why INBS Will Have Our Full Focus Tomorrow Morning—Tuesday, September 1, 2026…
1. Tight Float: According to Yahoo Finance, INBS has fewer than 3M shares listed as available to the public, a structure that can contribute to sharper moves when demand changes. 2. Recent Strength: With Monday’s profile reaching $1.58, INBS was approximately 42% above Friday’s $1.11 close heading into Tuesday. 3. Revenue Growth: Fiscal 2026 revenue reached $4.2M, giving INBS 38% year-over-year growth alongside expanding commercial activity. 4. Margin Expansion: Gross margin climbed to 48.63%, up 778 basis points, giving INBS another operating metric worth examining. 5. FDA Progress: All clinical data collection for the FDA 510(k) program is complete, with INBS targeting submission in H2 2026 for codeine detection clearance. 6. Installed Base: The reader installed base for INBS grew 22% year over year to 1,886 units, showing continued expansion in field deployment. 7. Cartridge Growth: Consumable cartridge usage reached 106,500 units, up 35% year over year, meaning INBS saw cartridge growth outpace reader-base growth. 8. Global Customers: With 502 active customers across the UK, Europe, APAC, and the Middle East, INBS already has an established commercial footprint outside the U.S. 9. Patent Protection: After securing its eighth European patent grant, INBS has continued adding intellectual-property protection around its proprietary fingerprint screening technology. 10. Faster Screening: A rapid screening cartridge targeting 70% faster results is currently in validation, giving INBS another product-development milestone to follow. Get Laser Focused On (INBS) Before Tomorrow Morning…
Intelligent Bio Solutions Inc. (Nasdaq: INBS) represents the kind of setup Street Ideas looks for — verified commercial traction, a differentiated technology, an approaching high-magnitude potential catalyst, and a float structure that amplifies everything. A company with 502 active customers, 38% revenue growth, expanding margins, a completed clinical data package, and a path to the world's largest addressable market in its sector — all sitting on a sub-3M share float. That is the kind of convergence that earns a spot at the top of the Street Ideas research list. Get laser focused on (INBS) before tomorrow morning. (INBS) will be up on our screen early, Tuesday, September 1, 2026. Sincerely, Paul Prescott
Co-Founder / Managing Editor
Street Ideas Newsletter |
Tidak ada komentar:
Posting Komentar